A patient-derived subrenal capsule xenograft model can predict response to adjuvant therapy for cancers in the head of the pancreas

Ang, 2014, The utility of immunohistochemistry in subtyping adenocarcinoma of the ampulla of vater, Am J Surg Pathol, 38, 1371, 10.1097/PAS.0000000000000230

Chang, 2013, Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater, J Clin Oncol, 31, 1348, 10.1200/JCO.2012.46.8868

Morini, 2013, Carcinoma of the ampulla of Vater: morphological and immunophenotypical classification predicts overall survival, Pancreas, 42, 60, 10.1097/MPA.0b013e318258fda8

Neoptolemos, 2010, Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial, JAMA, 304, 1073, 10.1001/jama.2010.1275

Oettle, 2007, Adjuvant therapy in pancreatic cancer: a critical appraisal, Drugs, 67, 2293, 10.2165/00003495-200767160-00001

Neoptolemos, 2003, Adjuvant therapy in pancreatic cancer: historical and current perspectives, Ann Oncol, 14, 675, 10.1093/annonc/mdg207

Neoptolemos, 2012, Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial, JAMA, 308, 147, 10.1001/jama.2012.7352

Rubio-Viqueira, 2006, An in vivo platform for translational drug development in pancreatic cancer, Clin Cancer Res, 12, 4652, 10.1158/1078-0432.CCR-06-0113

Garrido-Laguna, 2011, Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer, Clin Cancer Res, 17, 5793, 10.1158/1078-0432.CCR-11-0341

Jin, 2010, Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review, Clin Transl Oncol, 12, 473, 10.1007/s12094-010-0540-6

Cutz, 2006, Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes, Clin Cancer Res, 12, 4043, 10.1158/1078-0432.CCR-06-0252

Lin, 2010, Development of metastatic and non-metastatic tumor lines from a patient's prostate cancer specimen-identification of a small subpopulation with metastatic potential in the primary tumor, Prostate, 70, 1636, 10.1002/pros.21199

John, 2011, The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer, Clin Cancer Res, 17, 134, 10.1158/1078-0432.CCR-10-2224

Pereira, 2004, Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine, J Comput Chem, 25, 1286, 10.1002/jcc.20054

Andriulli, 2012, Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies, Ann Surg Oncol, 19, 1644, 10.1245/s10434-011-2110-8

Shi, 2012, Phase II trial of capecitabine combined with thalidomide in second-line treatment of advanced pancreatic cancer, Pancreatology, 12, 475, 10.1016/j.pan.2012.09.007

Klapdor, 2012, Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9, Anticancer Res, 32, 2191

Moore, 2007, Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 25, 1960, 10.1200/JCO.2006.07.9525

Berk, 2012, XELOX vs. FOLFOX4 as second line chemotherapy in advanced pancreatic cancer, Hepatogastroenterology, 59, 2635

Wang, 2005, Development and characterization of efficient xenograft models for benign and malignant human prostate tissue, Prostate, 64, 149, 10.1002/pros.20225

Wu, 2012, Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models, J Transl Med, 10, 180, 10.1186/1479-5876-10-180

Hamilton, 2012, Ki-67 predicts disease recurrence and poor prognosis in pancreatic neuroendocrine neoplasms, Surgery, 152, 107, 10.1016/j.surg.2012.02.011

Vang, 2006, Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases, Am J Surg Pathol, 30, 1130, 10.1097/01.pas.0000213281.43036.bb

Marechal, 2012, Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma, Gastroenterology, 143, 664, 10.1053/j.gastro.2012.06.006

Joyce, 2009, Microenvironmental regulation of metastasis, Nat Rev Cancer, 9, 239, 10.1038/nrc2618

Carmona-Fontaine, 2013, Emergence of spatial structure in the tumor microenvironment due to the Warburg effect, Proc Natl Acad Sci U S A, 110, 19402, 10.1073/pnas.1311939110

Sharpless, 2006, The mighty mouse: genetically engineered mouse models in cancer drug development, Nat Rev Drug Discov, 5, 741, 10.1038/nrd2110

Voskoglou-Nomikos, 2003, Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models, Clin Cancer Res, 9, 4227

Garcia, 2013, Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma, PLoS One, 8, e78183, 10.1371/journal.pone.0078183

Lee, 2005, Systemic administration of attenuated Salmonella choleraesuis in combination with cisplatin for cancer therapy, Mol Ther, 11, 707, 10.1016/j.ymthe.2005.01.008

Rothenberg, 1996, A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer, Ann Oncol, 7, 347, 10.1093/oxfordjournals.annonc.a010600

Von Hoff, 2013, Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 1691, 10.1056/NEJMoa1304369

Vaccaro, 2011, FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, N Engl J Med, 365, 768, 10.1056/NEJMc1107627

Andersson, 2009, Gemcitabine chemoresistance in pancreatic cancer: molecular mechanisms and potential solutions, Scand J Gastroenterol, 44, 782, 10.1080/00365520902745039

Hodge, 2011, Effect of its deaminated metabolite, 2',2'-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells, Biochem Pharmacol, 81, 950, 10.1016/j.bcp.2011.01.016

Hodge, 2011, The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase, Drug Metab Dispos, 39, 2013, 10.1124/dmd.111.040790

Greenhalf, 2014, Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial, J Natl Cancer Inst, 106, djt347, 10.1093/jnci/djt347

Poplin, 2013, Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity, J Clin Oncol, 31, 4453, 10.1200/JCO.2013.51.0826

Neesse, 2011, Stromal biology and therapy in pancreatic cancer, Gut, 60, 861, 10.1136/gut.2010.226092

Kulbe, 2012, A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment, Cancer Res, 72, 66, 10.1158/0008-5472.CAN-11-2178

Tripathi, 2012, Understanding the role of stromal fibroblasts in cancer progression, Cell Adh Migr, 6, 231, 10.4161/cam.20419

Olive, 2009, Inhibition of hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer, Science, 324, 1457, 10.1126/science.1171362

Dong, 2010, Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy, Clin Cancer Res, 16, 1442, 10.1158/1078-0432.CCR-09-2878